TY  - JOUR
AU  - Antonijević, Nebojša
AU  - Živković, Ivana D.
AU  - Jovanović, Ljubica M.
AU  - Matić, Dragan
AU  - Kocica, Mladen J.
AU  - Mrdović, Igor
AU  - Kanjuh, Vladimir
AU  - Ćulafić, Milica
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2783
AB  - Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug's efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug's safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Drug Metabolism
T1  - Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions
VL  - 18
IS  - 7
SP  - 622
EP  - 635
DO  - 10.2174/1389200218666170427113504
ER  - 

@article{
author = "Antonijević, Nebojša and Živković, Ivana D. and Jovanović, Ljubica M. and Matić, Dragan and Kocica, Mladen J. and Mrdović, Igor and Kanjuh, Vladimir and Ćulafić, Milica",
year = "2017",
abstract = "Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug's efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug's safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Drug Metabolism",
title = "Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions",
volume = "18",
number = "7",
pages = "622-635",
doi = "10.2174/1389200218666170427113504"
}

Antonijević, N., Živković, I. D., Jovanović, L. M., Matić, D., Kocica, M. J., Mrdović, I., Kanjuh, V.,& Ćulafić, M.. (2017). Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. in Current Drug Metabolism
Bentham Science Publ Ltd, Sharjah., 18(7), 622-635.
https://doi.org/10.2174/1389200218666170427113504

Antonijević N, Živković ID, Jovanović LM, Matić D, Kocica MJ, Mrdović I, Kanjuh V, Ćulafić M. Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. in Current Drug Metabolism. 2017;18(7):622-635.
doi:10.2174/1389200218666170427113504 .

Antonijević, Nebojša, Živković, Ivana D., Jovanović, Ljubica M., Matić, Dragan, Kocica, Mladen J., Mrdović, Igor, Kanjuh, Vladimir, Ćulafić, Milica, "Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions" in Current Drug Metabolism, 18, no. 7 (2017):622-635,
https://doi.org/10.2174/1389200218666170427113504 . .

TY  - JOUR
AU  - Radovanović, N.
AU  - Antonijević, N.
AU  - Beletić, Anđelo
AU  - Perunicić, J.
AU  - Kocica, Mladen J.
AU  - Mirković, Duško
AU  - Lacković, Vesna
AU  - Lacković, Milena
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1326
AB  - Investigation of hyperhomocysteinemia (HHcy) as an important risk factor for pulmonary thromboembolism (PTE), which represents a most dangerous consequence of a unique phenomenon of venous thromboembolism which still suffers from sometimes conflicting or inadequately clarified results. The role of homocysteine in the clinical manifestation of this life-threatening disease and its treatment (in which any further information may be decisive) requires detailed examination. The purpose of this study is to determine the differences in HHcy incidence and homocysteinemia levels between patients with PTE and healthy persons. The study enrolled 70 patients with PTE and 50 healthy persons. Homocysteine was measured using the HPLC method with fluorescent detection and HHcy was defined as homocysteinemia above 12 mu mol/L. Statistical analyses included chi-square and Mann Whitney U tests. The median homocysteinemia value was significantly higher (p=0.017) in the patients (12.10 mu mol/L) than in the controls (10.35 mu mol/L). The comparison of HHcy incidence between the patients (51.5%) and controls (30%) revealed a significant difference (p=0.021). In patients, homocysteinemia was significantly higher (p=0.002) in men (14.05 mu mol/L) than in women (10.01 mu mol/L) HHcy was present in 67.6% of men with PTE, which was significantly higher (p=0.006) than the incidence in women with PTE (33.3%). Healthy males had significantly higher (p=0.001) homocysteinemia (12.54 mu mol/L) than healthy females (9.4 mu mol/L). A significant difference (p=0.031) was observed between the incidences of HHcy in healthy males (44.0%) and healthy females (16.0%). We conclude that the incidence of hyperhomocysteinemia and homocysteinemia are significantly higher in all the patients compared with de healthy persons, as well as in both healthy males and males with PTE compared with healthy females and female patients. This indicates that HHcy findings in PE are likely to have a clinical importance.
PB  - Srpsko biološko društvo, Beograd, i dr.
T2  - Archives of Biological Sciences
T1  - Hyperhomocysteinemia in patients with pulmonary embolism
VL  - 62
IS  - 4
SP  - 907
EP  - 914
DO  - 10.2298/ABS1004907R
ER  - 

@article{
author = "Radovanović, N. and Antonijević, N. and Beletić, Anđelo and Perunicić, J. and Kocica, Mladen J. and Mirković, Duško and Lacković, Vesna and Lacković, Milena",
year = "2010",
abstract = "Investigation of hyperhomocysteinemia (HHcy) as an important risk factor for pulmonary thromboembolism (PTE), which represents a most dangerous consequence of a unique phenomenon of venous thromboembolism which still suffers from sometimes conflicting or inadequately clarified results. The role of homocysteine in the clinical manifestation of this life-threatening disease and its treatment (in which any further information may be decisive) requires detailed examination. The purpose of this study is to determine the differences in HHcy incidence and homocysteinemia levels between patients with PTE and healthy persons. The study enrolled 70 patients with PTE and 50 healthy persons. Homocysteine was measured using the HPLC method with fluorescent detection and HHcy was defined as homocysteinemia above 12 mu mol/L. Statistical analyses included chi-square and Mann Whitney U tests. The median homocysteinemia value was significantly higher (p=0.017) in the patients (12.10 mu mol/L) than in the controls (10.35 mu mol/L). The comparison of HHcy incidence between the patients (51.5%) and controls (30%) revealed a significant difference (p=0.021). In patients, homocysteinemia was significantly higher (p=0.002) in men (14.05 mu mol/L) than in women (10.01 mu mol/L) HHcy was present in 67.6% of men with PTE, which was significantly higher (p=0.006) than the incidence in women with PTE (33.3%). Healthy males had significantly higher (p=0.001) homocysteinemia (12.54 mu mol/L) than healthy females (9.4 mu mol/L). A significant difference (p=0.031) was observed between the incidences of HHcy in healthy males (44.0%) and healthy females (16.0%). We conclude that the incidence of hyperhomocysteinemia and homocysteinemia are significantly higher in all the patients compared with de healthy persons, as well as in both healthy males and males with PTE compared with healthy females and female patients. This indicates that HHcy findings in PE are likely to have a clinical importance.",
publisher = "Srpsko biološko društvo, Beograd, i dr.",
journal = "Archives of Biological Sciences",
title = "Hyperhomocysteinemia in patients with pulmonary embolism",
volume = "62",
number = "4",
pages = "907-914",
doi = "10.2298/ABS1004907R"
}

Radovanović, N., Antonijević, N., Beletić, A., Perunicić, J., Kocica, M. J., Mirković, D., Lacković, V.,& Lacković, M.. (2010). Hyperhomocysteinemia in patients with pulmonary embolism. in Archives of Biological Sciences
Srpsko biološko društvo, Beograd, i dr.., 62(4), 907-914.
https://doi.org/10.2298/ABS1004907R

Radovanović N, Antonijević N, Beletić A, Perunicić J, Kocica MJ, Mirković D, Lacković V, Lacković M. Hyperhomocysteinemia in patients with pulmonary embolism. in Archives of Biological Sciences. 2010;62(4):907-914.
doi:10.2298/ABS1004907R .

Radovanović, N., Antonijević, N., Beletić, Anđelo, Perunicić, J., Kocica, Mladen J., Mirković, Duško, Lacković, Vesna, Lacković, Milena, "Hyperhomocysteinemia in patients with pulmonary embolism" in Archives of Biological Sciences, 62, no. 4 (2010):907-914,
https://doi.org/10.2298/ABS1004907R . .